Related Experiment Videos
Dendritic cells: immunological features and utilisation for tumour immunotherapy
1Nuffield Department of Clinical Medicine, University of Oxford, John Radcliffe Hospital II, Headington, OX3 9DU, UK. preay@worf.molbiol.ox.ac.uk
Abstract:
The prospect of developing 'magic bullets' to attack tumour cells has been a goal of biologists for decades. Abundant experimental and clinical observations demonstrating that an effective specific immune response may engender tumour regression has prompted efforts to find an immunotherapeutic approach to this problem. The most important arm of cellular immunity for such responses appears to be cytotoxic T-lymphocytes (CTL) which can recognise antigen on virtually all cell types and which are key to the elimination of virally-infected cells. The specific activation and maintenance of activity of these cells is therefore the major goal of designing a therapeutic cancer vaccine. Advances in our understanding of the role of dendritic cells (DC) in priming and modifying immune responses suggest that they should be potent adjuvants for vaccination. The use of antigens targeted to the major histocompatibility complex (MHC) molecules expressed on these cells as an approach to tumour immunotherapy has already been tested in the treatment of many malignancies, and recent findings shed light on additional directions through which their efficacy may be improved.
Insights
Developing therapeutic cancer vaccines aims to activate cytotoxic T-lymphocytes (CTLs) for tumor regression. Dendritic cells (DCs) are key to priming these immune responses, offering a promising avenue for cancer immunotherapy.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- The development of targeted cancer therapies, often termed 'magic bullets,' has long been a goal in cancer research.
- Tumor regression observed with effective specific immune responses highlights the potential of cancer immunotherapy.
- Cytotoxic T-lymphocytes (CTLs) are crucial for cellular immunity, recognizing antigens on most cell types and eliminating infected cells.
Purpose of the Study:
- To explore the activation and maintenance of cytotoxic T-lymphocytes (CTLs) as a primary objective for therapeutic cancer vaccine design.
- To investigate the role of dendritic cells (DCs) as potent adjuvants in cancer vaccination strategies.
- To enhance the efficacy of tumor immunotherapy by targeting antigens to major histocompatibility complex (MHC) molecules on DCs.
Main Methods:
- Leveraging advances in understanding dendritic cell (DC) function in immune response priming and modulation.
- Utilizing antigens targeted to major histocompatibility complex (MHC) molecules expressed on dendritic cells.
- Reviewing experimental and clinical observations of immune responses in tumor regression.
Main Results:
- Dendritic cells (DCs) show potential as powerful adjuvants for vaccination due to their role in immune priming.
- Targeting antigens to MHC molecules on DCs has been tested in various malignancies for tumor immunotherapy.
- Recent findings suggest new strategies to improve the efficacy of DC-based cancer vaccines.
Conclusions:
- Activating and maintaining cytotoxic T-lymphocyte (CTL) activity is central to developing effective therapeutic cancer vaccines.
- Dendritic cell (DC)-based immunotherapy, particularly antigen targeting to MHC molecules, represents a promising approach for cancer treatment.
- Ongoing research continues to uncover novel directions for enhancing the effectiveness of these immunotherapeutic strategies.